KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Invested Capital (2016 - 2025)

West Pharmaceutical Services' Invested Capital history spans 17 years, with the latest figure at $202.8 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 92.97% year-over-year to $202.8 million; the TTM value through Dec 2025 reached $273.5 million, down 90.52%, while the annual FY2025 figure was $202.8 million, 92.97% down from the prior year.
  • Invested Capital for Q4 2025 was $202.8 million at West Pharmaceutical Services, down from $3.3 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $3.3 billion in Q3 2025 and bottomed at $202.8 million in Q4 2025.
  • The 5-year median for Invested Capital is $2.9 billion (2024), against an average of $2.7 billion.
  • The largest annual shift saw Invested Capital increased 24.4% in 2021 before it crashed 92.97% in 2025.
  • A 5-year view of Invested Capital shows it stood at $2.6 billion in 2021, then increased by 11.8% to $2.9 billion in 2022, then increased by 6.7% to $3.1 billion in 2023, then fell by 6.57% to $2.9 billion in 2024, then plummeted by 92.97% to $202.8 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Invested Capital are $202.8 million (Q4 2025), $3.3 billion (Q3 2025), and $3.1 billion (Q2 2025).